John Cox (file photo)
Investors throw $189M at Flagship startup's mission to 'decode' interactions between T cells and antigens
Two is often better than one in the world of biopharma investment. If you need proof, look no further than Repertoire Immune Medicines.
Repertoire launched …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
